HC Wainwright Increases Dianthus Therapeutics (NASDAQ:DNTH) Price Target to $130.00

Key Points

• HC Wainwright raised its price target on Dianthus from $47 to $130 and reiterated a buy rating — the lift (and similar target increases from other firms) pushed the consensus target to about $96.78 and helped fuel the stock rally.
• The immediate catalyst was an early GO decision in the Phase 3 CAPTIVATE trial after an interim responder analysis met criteria, with the company keeping the 300 mg S.C. Q2W dose and planning regulatory discussions about the 600 mg dose.
• Despite the upbeat clinical news, Dianthus posted a Q4 EPS miss (−$1.43 vs. −$0.97 expected) and very negative margins/ROE, though institutional ownership has risen to roughly 47.5%, signaling significant investor interest amid the risk.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) had its price objective boosted by analysts at HC Wainwright from $47.00 to $130.00 in a research report issued to clients and investors on Monday,Benzinga reports. The brokerage currently has a "buy" rating on the stock. HC Wainwright's price target points to a potential upside of 69.50% from the company's current price.

Other research analysts have also issued research reports about the stock. Jefferies Financial Group raised their price objective on shares of Dianthus Therapeutics from $66.00 to $81.00 and gave the company a "buy" rating in a research note on Monday, February 2nd. Truist Financial boosted their price objective on shares of Dianthus Therapeutics from $63.00 to $110.00 and gave the stock a "buy" rating in a research report on Monday. TD Cowen restated a "buy" rating on shares of Dianthus Therapeutics in a report on Monday. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Dianthus Therapeutics in a report on Wednesday, January 21st. Finally, Stifel Nicolaus set a $120.00 price objective on shares of Dianthus Therapeutics in a research note on Monday. Eleven research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $96.78.

Dianthus Therapeutics Trading Up 17.6%

DNTH stock traded up $11.50 during trading on Monday, reaching $76.70. 3,006,667 shares of the stock were exchanged, compared to its average volume of 870,649. The firm has a market capitalization of $3.31 billion, a price-to-earnings ratio of -22.10 and a beta of 1.56. The business has a 50 day moving average price of $48.42 and a 200-day moving average price of $40.78. Dianthus Therapeutics has a 1 year low of $13.36 and a 1 year high of $84.86.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last released its quarterly earnings results on Monday, March 9th. The company reported ($1.43) EPS for the quarter, missing the consensus estimate of ($0.97) by ($0.46). The firm had revenue of $0.57 million for the quarter, compared to analysts' expectations of $0.40 million. Dianthus Therapeutics had a negative net margin of 4,106.04% and a negative return on equity of 33.02%. On average, research analysts anticipate that Dianthus Therapeutics will post -2.61 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Fairmount Funds Management LLC lifted its holdings in shares of Dianthus Therapeutics by 22.2% in the third quarter. Fairmount Funds Management LLC now owns 3,307,191 shares of the company's stock valued at $130,138,000 after purchasing an additional 600,000 shares in the last quarter. Vestal Point Capital LP increased its holdings in shares of Dianthus Therapeutics by 88.2% in the 2nd quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company's stock valued at $59,616,000 after purchasing an additional 1,499,931 shares during the period. Wellington Management Group LLP lifted its position in shares of Dianthus Therapeutics by 3,366.9% in the third quarter. Wellington Management Group LLP now owns 2,577,662 shares of the company's stock worth $101,431,000 after purchasing an additional 2,503,311 shares in the last quarter. Vanguard Group Inc. grew its position in Dianthus Therapeutics by 24.7% during the fourth quarter. Vanguard Group Inc. now owns 2,048,452 shares of the company's stock valued at $84,417,000 after purchasing an additional 406,254 shares in the last quarter. Finally, TCG Crossover Management LLC increased its stake in Dianthus Therapeutics by 11.7% in the 3rd quarter. TCG Crossover Management LLC now owns 1,676,624 shares of the company's stock valued at $65,975,000 after buying an additional 175,000 shares during the period. 47.53% of the stock is currently owned by institutional investors and hedge funds.

Key Dianthus Therapeutics News

Here are the key news stories impacting Dianthus Therapeutics this week:

• Positive Sentiment: Dianthus announced an early GO decision in the Phase 3 CAPTIVATE trial after meeting responder criteria (20 confirmed responders) with fewer than the planned participants — company will keep the 300mg S.C. Q2W dose and plans to discuss removing the 600mg dose with regulators. This is the main catalyst driving the rally. Dianthus Announces Early GO Decision
• Positive Sentiment: The company highlighted the GO decision and Q4/FY results in its investor release, stressing that key CAPTIVATE objectives were achieved ahead of Q2 guidance. Highlights Recent Business Achievements
• Positive Sentiment: Dianthus scheduled a conference call/webcast to discuss the interim responder analysis — management access and Q&A typically help reinforce investor confidence after trial readouts. Conference Call & Webcast Announcement
• Positive Sentiment: Truist raised its price target from $63 to $110 and maintained a Buy — analyst upgrade/target lift provides third-party validation and likely supported the share uptick. Benzinga PT Raise
• Positive Sentiment: Press and commentary noted the stock's strong multi-year appreciation and tied the surge to the CIDP readout — momentum and positive narrative amplified buying. Investors.com: What's Going On?
• Neutral Sentiment: Valuation commentary and analyst write-ups are evaluating DNTH after a strong run; these pieces frame potential upside but don't change clinical facts. Yahoo Finance Valuation Piece
• Negative Sentiment: Q4 results: Dianthus reported a larger-than-expected loss (EPS -$1.43 vs. consensus ~ -$0.97) and extremely negative margins/ROE — the miss is a near-term financial headwind and explains some profit-taking pressure. Zacks: Q4 Loss, Miss

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.